JP6324887B2 - 血清アルブミンに結合するタンパク質 - Google Patents

血清アルブミンに結合するタンパク質 Download PDF

Info

Publication number
JP6324887B2
JP6324887B2 JP2014516279A JP2014516279A JP6324887B2 JP 6324887 B2 JP6324887 B2 JP 6324887B2 JP 2014516279 A JP2014516279 A JP 2014516279A JP 2014516279 A JP2014516279 A JP 2014516279A JP 6324887 B2 JP6324887 B2 JP 6324887B2
Authority
JP
Japan
Prior art keywords
alb
seq
polypeptide
amino acid
nanobodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014516279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520129A (ja
Inventor
ドンブレヒト，ブルーノ
スホット，ピーテル
フェルフェルケン，セドリック・ヨーゼフ・ネオテレ
Original Assignee
アブリンクス エン．ヴェー．
アブリンクス エン．ヴェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブリンクス エン．ヴェー．, アブリンクス エン．ヴェー． filed Critical アブリンクス エン．ヴェー．
Publication of JP2014520129A publication Critical patent/JP2014520129A/ja
Application granted granted Critical
Publication of JP6324887B2 publication Critical patent/JP6324887B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014516279A 2011-06-23 2012-06-14 血清アルブミンに結合するタンパク質 Active JP6324887B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161500464P 2011-06-23 2011-06-23
US61/500,464 2011-06-23
PCT/EP2012/061304 WO2012175400A1 (en) 2011-06-23 2012-06-14 Serum albumin binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018076201A Division JP6843090B2 (ja) 2011-06-23 2018-04-11 血清アルブミンに結合するタンパク質

Publications (2)

Publication Number Publication Date
JP2014520129A JP2014520129A (ja) 2014-08-21
JP6324887B2 true JP6324887B2 (ja) 2018-05-16

Family

ID=46298413

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014516279A Active JP6324887B2 (ja) 2011-06-23 2012-06-14 血清アルブミンに結合するタンパク質
JP2018076201A Active JP6843090B2 (ja) 2011-06-23 2018-04-11 血清アルブミンに結合するタンパク質
JP2021026177A Active JP7304375B2 (ja) 2011-06-23 2021-02-22 血清アルブミンに結合するタンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018076201A Active JP6843090B2 (ja) 2011-06-23 2018-04-11 血清アルブミンに結合するタンパク質
JP2021026177A Active JP7304375B2 (ja) 2011-06-23 2021-02-22 血清アルブミンに結合するタンパク質

Country Status (17)

Country Link
US (2) US9573992B2 (enExample)
EP (3) EP4218933A1 (enExample)
JP (3) JP6324887B2 (enExample)
CN (2) CN106046168A (enExample)
AU (1) AU2012271974B2 (enExample)
CA (1) CA2839779C (enExample)
CY (1) CY1122691T1 (enExample)
DK (1) DK2723771T3 (enExample)
ES (1) ES2759936T3 (enExample)
HR (2) HRP20192160T1 (enExample)
HU (1) HUE047238T2 (enExample)
IN (1) IN2014CN00414A (enExample)
LT (1) LT2723771T (enExample)
PL (1) PL2723771T3 (enExample)
PT (1) PT2723771T (enExample)
SI (1) SI2723771T1 (enExample)
WO (1) WO2012175400A1 (enExample)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
EP4218933A1 (en) * 2011-06-23 2023-08-02 Ablynx NV Serum albumin binding proteins
FI2974737T3 (fi) 2011-06-23 2026-01-22 Ablynx Nv Tekniikoita tietyn proteiinihäiriön ennakoimiseksi, havaitsemiseksi ja vähentämiseksi immunoglobuliinin yhtä muuttuvaa domeenia käsittävissä määrityksissä
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
EP2747783B1 (en) * 2011-09-30 2017-06-14 Ablynx N.V. Biological materials related to c-met
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
HUE056738T2 (hu) 2014-05-16 2022-03-28 Ablynx Nv Eljárás gyógyszer elleni antitestek, különösen kezelés kapcsán kialakuló gyógyszer elleni antitestek detektálására és/vagy mérésére
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
KR20180091115A (ko) 2014-05-16 2018-08-14 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US11426468B2 (en) 2014-12-19 2022-08-30 Ablynx N.V. Cysteine linked nanobody dimers
CN107531781B (zh) 2015-01-29 2021-12-07 抗菌技术,生物技术研究与发展股份有限公司 用于阿尔茨海默病和相关紊乱的抗体分子和肽递送系统
WO2016187594A1 (en) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
NO2768984T3 (enExample) 2015-11-12 2018-06-09
EP3974449A1 (en) 2015-11-13 2022-03-30 Ablynx NV Improved serum albumin-binding immunoglobulin variable domains
CN114605530B (zh) 2015-11-18 2025-06-10 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
JO3740B1 (ar) 2015-11-18 2021-01-31 Merck Sharp & Dohme روابط pd1/ctla4
TW202216787A (zh) 2015-11-18 2022-05-01 美商默沙東藥廠 Pd1及／或 lag3結合劑
CA3004900C (en) 2015-11-18 2021-08-10 Merck Sharp & Dohme Corp. Ctla4 binders
SG11201803976VA (en) * 2015-11-27 2018-06-28 Ablynx Nv Polypeptides inhibiting cd40l
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7101621B2 (ja) * 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
MX2018016413A (es) 2016-06-23 2019-05-09 Ablynx Nv Ensayos farmacocineticos mejorados para dominios variables unicos de inmunoglobulina.
JP7222888B2 (ja) 2016-11-16 2023-02-15 アブリンクス エン．ヴェー． Ｃｄ１２３及びｔｃｒアルファ／ベータに結合することが可能なｔ細胞動員ポリペプチド
MX2019006574A (es) * 2016-12-07 2019-08-21 Ablynx Nv Aglutinantes de albumina de suero mejorados.
CN107674122A (zh) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 一种识别人血清白蛋白的单域抗体
IL312292A (en) 2017-01-17 2024-06-01 Ablynx Nv Improved serum albumin binders
CA3050574A1 (en) * 2017-01-17 2018-07-26 Ablynx Nv Improved serum albumin binders
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN110546506B (zh) 2017-03-31 2023-04-04 埃博灵克斯股份有限公司 改进的免疫原性测定法
IL300964A (en) 2017-05-12 2023-04-01 Harpoon Therapeutics Inc mesothelin binding proteins
PE20201183A1 (es) 2017-10-13 2020-11-03 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CN111655296A (zh) * 2018-02-26 2020-09-11 埃博灵克斯股份有限公司 编码肽接头的经改良核苷酸序列
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CN110964107B (zh) * 2018-09-30 2022-08-09 苏州康宁杰瑞生物科技有限公司 Met结合分子、其组合和用途
CN111138537B (zh) * 2018-11-06 2021-07-09 瑞阳(苏州)生物科技有限公司 一种抗人血清白蛋白抗体片段、制备方法和应用
CN111138536B (zh) * 2018-11-06 2021-07-09 瑞阳(苏州)生物科技有限公司 抗人血清白蛋白单域抗体的制备及其应用
CN114245806A (zh) 2019-05-14 2022-03-25 哈普恩治疗公司 EpCAM结合蛋白及使用方法
WO2020229844A1 (en) * 2019-05-15 2020-11-19 Crescendo Biologics Limited Binding molecules
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN114981300B (zh) 2019-12-06 2025-10-31 艾伯霖克斯公司 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
BR112022010231A2 (pt) 2019-12-06 2022-09-06 Ablynx Nv Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a tnfalfa e ox40l
TWI861302B (zh) 2019-12-09 2024-11-11 比利時商艾伯霖克斯公司 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
CN110988361B (zh) * 2019-12-13 2020-09-18 山东民康生物科技有限公司 人血清白蛋白去除试剂盒
EP4087875B1 (en) 2020-01-08 2024-08-28 Argenx BV Antagonists of human neonatal fc receptor (fcrn) for treating pemphigus disorders
AU2021224851A1 (en) 2020-02-21 2022-09-15 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
JP2023519967A (ja) 2020-03-30 2023-05-15 アブリンクス・エヌ・フェー 多価免疫グロブリン単一可変ドメインの製造及び精製のための方法
BR112023005273A2 (pt) 2020-09-25 2023-04-25 Ablynx Nv Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a il-13 e ox40l
CN112142846B (zh) * 2020-10-10 2022-07-08 西北大学 Aox特异性抗体组合及其制备方法和用途
CN115244076B (zh) * 2020-10-27 2023-08-04 北京质肽生物医药科技有限公司 Gdf15融合蛋白及其用途
JP2023549537A (ja) * 2020-11-16 2023-11-27 エイビー セラピューティクス インコーポレイテッド 多重特異性抗体およびその使用方法
TW202241948A (zh) 2020-12-18 2022-11-01 比利時商艾伯霖克斯公司 基於TCR α/β反應性的T細胞募集多肽
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
AU2021399955A1 (en) 2020-12-18 2023-08-03 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
CN116635402B (zh) 2021-07-14 2024-03-15 北京质肽生物医药科技有限公司 用于代谢病症的融合多肽
WO2023088295A1 (zh) * 2021-11-17 2023-05-25 江苏先声药业有限公司 一种多特异性抗体及其药物用途
EP4448574A1 (en) 2021-12-17 2024-10-23 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123
CN118139892A (zh) * 2022-01-14 2024-06-04 浙江道尔生物科技有限公司 一种三靶点抗肿瘤药物、其制备方法及其应用
JP2025530888A (ja) 2022-06-14 2025-09-18 アブリンクス エン．ヴェー． Ｔ細胞レセプターを標的とするイムノグロブリン単一可変ドメイン
JP2025518971A (ja) 2022-06-15 2025-06-19 アルジェニクス ビーブイ ｐＨ依存性ＨＳＡ結合分子及び使用方法
TW202423965A (zh) 2022-07-27 2024-06-16 比利時商艾伯霖克斯公司 與新生兒fc受體的特定表位結合之多肽
WO2024084203A1 (en) 2022-10-18 2024-04-25 Isogenica Limited Single domain antibodies binding to albumin
EP4640700A1 (en) 2022-12-19 2025-10-29 Harbour Biomed (Shanghai) Co., Ltd "kappa/lambda" fab-fab series-connection multi-specific binding protein, preparation thereof, and use thereof
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
EP4648792A2 (en) 2023-01-09 2025-11-19 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
KR20250135288A (ko) * 2023-01-18 2025-09-12 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 융합 폴리펩타이드의 액체 약학 조성물 및 이의 사용 방법
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
WO2024192065A1 (en) 2023-03-14 2024-09-19 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
US20240383958A1 (en) 2023-04-11 2024-11-21 Visterra, Inc. Apelin receptor agonists and uses thereof
WO2024231348A1 (en) 2023-05-11 2024-11-14 Vib Vzw Slc4a4/nbce1 inhibitors
WO2024238790A1 (en) 2023-05-17 2024-11-21 Odyssey Therapeutics, Inc. Modified single-domain antibodies
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
WO2025006846A2 (en) 2023-06-29 2025-01-02 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
TW202525843A (zh) 2023-09-04 2025-07-01 法商賽諾菲公司 用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025085553A1 (en) 2023-10-16 2025-04-24 Paragon Therapeutics, Inc. Fcrn antagonists with improved half-life and methods of use
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025114529A1 (en) 2023-12-01 2025-06-05 Ablynx Nv Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025217488A1 (en) * 2024-04-12 2025-10-16 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
US12459994B2 (en) * 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2026008664A1 (en) 2024-07-01 2026-01-08 Vib Vzw Allosteric modulators of inhibitory immune receptor complexes

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
EP0698097B1 (en) 1993-04-29 2001-08-16 Unilever N.V. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ATE461282T1 (de) 1997-10-27 2010-04-15 Bac Ip Bv Multivalente antigenbindende proteine
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
KR20050092029A (ko) 2003-01-10 2005-09-16 아블린쓰 엔.브이. 폰 빌레브란트 인자(ｖＷＦ) 또는 콜라겐에 대한낙타과로부터의 재조합 ＶＨＨ 단일 도메인 항체
ATE465181T1 (de) * 2004-08-05 2010-05-15 Genentech Inc Humanisierte anti-cmet-antagonisten
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
WO2006129843A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
CA2640066A1 (en) 2006-01-24 2007-08-02 Roland Beckmann Fusion proteins that contain natural junctions
BRPI0709917A2 (pt) * 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
CA2658612C (en) 2006-08-03 2015-11-17 Astrazeneca Ab Antibodies directed to .alpha.v.beta.6 and uses thereof
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
CN101528767A (zh) * 2006-10-11 2009-09-09 埃博灵克斯股份有限公司 以基本不依赖pH的方式结合血清蛋白的氨基酸序列、包括其的化合物、及其用途
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
US8623361B2 (en) 2007-05-24 2014-01-07 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2201040A1 (en) 2007-09-24 2010-06-30 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
KR20100097716A (ko) 2007-11-27 2010-09-03 아블린쓰 엔.브이. 이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
EP2250201B1 (en) 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
BRPI0911984A2 (pt) 2008-05-16 2016-09-20 Ablynx Nv sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos
HUE042053T2 (hu) 2008-06-05 2019-06-28 Ablynx Nv Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
WO2010042815A2 (en) 2008-10-09 2010-04-15 Duke University Vhh antibody fragments for use in the detection and treatment of cancer
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
CA2756853A1 (en) * 2009-03-27 2010-09-30 Christopher Herring Drug fusions and conjugates
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
AU2010331807B2 (en) 2009-12-18 2016-08-04 Sanofi Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
CA2788275A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim International Gmbh Biparatopic abeta binding polypeptides
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP4218933A1 (en) * 2011-06-23 2023-08-02 Ablynx NV Serum albumin binding proteins
US20150344568A1 (en) 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
FI2974737T3 (fi) 2011-06-23 2026-01-22 Ablynx Nv Tekniikoita tietyn proteiinihäiriön ennakoimiseksi, havaitsemiseksi ja vähentämiseksi immunoglobuliinin yhtä muuttuvaa domeenia käsittävissä määrityksissä
EA027160B1 (ru) 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met

Also Published As

Publication number Publication date
US20170210789A1 (en) 2017-07-27
AU2012271974B2 (en) 2017-01-12
JP2021088585A (ja) 2021-06-10
HRP20170535T4 (hr) 2022-08-19
CY1122691T1 (el) 2021-03-12
US20140228546A1 (en) 2014-08-14
US9573992B2 (en) 2017-02-21
PT2723771T (pt) 2019-12-11
ES2759936T3 (es) 2020-05-12
LT2723771T (lt) 2019-12-10
WO2012175400A1 (en) 2012-12-27
EP2723771A1 (en) 2014-04-30
JP7304375B2 (ja) 2023-07-06
JP2014520129A (ja) 2014-08-21
JP6843090B2 (ja) 2021-03-17
HUE047238T2 (hu) 2020-04-28
HRP20192160T1 (hr) 2020-02-21
EP4218933A1 (en) 2023-08-02
PL2723771T3 (pl) 2020-04-30
DK2723771T3 (da) 2019-12-02
CN103619878B (zh) 2016-10-26
JP2018127478A (ja) 2018-08-16
CN106046168A (zh) 2016-10-26
CA2839779A1 (en) 2012-12-27
CN103619878A (zh) 2014-03-05
SI2723771T1 (sl) 2019-12-31
HRP20170535T1 (hr) 2017-06-16
EP3466972A1 (en) 2019-04-10
EP2723771B1 (en) 2019-09-11
AU2012271974A1 (en) 2013-12-12
IN2014CN00414A (enExample) 2015-04-03
CA2839779C (en) 2020-10-06

Similar Documents

Publication Publication Date Title
JP7304375B2 (ja) 血清アルブミンに結合するタンパク質
JP7453206B2 (ja) 改良された血清アルブミン結合剤
EP3571225B1 (en) Improved serum albumin binders
EP3571224B1 (en) Improved serum albumin binders
US11142569B2 (en) Serum albumin-binding immunoglobulin variable domains
EP1888641B1 (en) Serum albumin binding proteins
CN101646689A (zh) 具有长半衰期的血清清蛋白结合蛋白
HK40098374A (en) Serum albumin binding proteins
HK40117444A (en) Improved serum albumin binders
HK40118030A (en) Improved serum albumin binders
HK40116819A (en) Improved serum albumin binders
HK40119626A (en) Improved serum albumin binders
CA3005061C (en) Improved serum albumin-binding immunoglobulin variable domains
WO2025098472A1 (zh) 融合蛋白及其医药用途
HK40017968A (en) Improved serum albumin binders
HK40017968B (en) Improved serum albumin binders
HK40018516A (en) Improved serum albumin binders
HK40018516B (en) Improved serum albumin binders

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180313

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180411

R150 Certificate of patent or registration of utility model

Ref document number: 6324887

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250